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Anemia is an important prognostic factor in hemodialysis patients. It has been reported that
parathyroidectomy ameliorates anemia and reduces the requirement of postoperative
erythropoiesis-stimulating agents. The objective of this study was to assess the effect of
cinacalcet, which is considered as a pharmacological parathyroidectomy, on anemia in
hemodialysis patients.
Methods
We used data from a prospective cohort of Japanese hemodialysis patients with secondary
hyperparathyroidism; the criteria were: intact parathyroid hormone concentrations 180
pg/mL or use of an intravenous or oral vitamin D receptor activator. All patients were cina-
calcet-naïve at study enrollment. The main outcome measure was achievement of the tar-
get hemoglobin level (10.0 g/dL), which was measured repeatedly every 6 months.
Cinacalcet exposure was defined as cumulative time since initiation. Both conventional lon-
gitudinal models and marginal structural models were adjusted for confounding factors.
Results
Among 3,201 cinacalcet-naïve individuals at baseline, cinacalcet was initiated in 1,337 indi-
viduals during the follow up. Cinacalcet users were slightly younger; included more patients
with chronic glomerulonephritis and fewer with diabetes; were more likely to have a history
of parathyroidectomy; and were more often on activated vitamin D agents, phosphate bind-
ers, and iron supplements. After adjusting for both time-invariant and time-varying potential
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confounders, including demographics, comorbidities, comedications, and laboratory val-
ues, each additional 6-month duration on cinacalcet was associated with a 1.1-fold
increase in the odds of achieving the target hemoglobin level.
Conclusions
Cinacalcet may improve anemia in chronic hemodialysis patients with secondary hyper-
parathyroidism, possibly through pathways both within and outside the parathyroid hor-
mone pathways. Further investigations are warranted to delineate the roles of cinacalcet
not only in the management of chronic kidney disease–mineral and bone disorder but also
in anemia control.
Introduction
Anemia is an important complication of chronic maintenance hemodialysis and is known to
be an important predictor of poor prognosis[1,2].Many factors contribute to anemia in dialysis
patients, such as decreased production of erythropoietin, resistance to erythropoietin, short-
ened survival of red blood cells (RBC), and diminished erythropoiesis[3–5].Additionally, sec-
ondary hyperparathyroidism (SHPT), a major component of chronic kidney disease–mineral
and bone disorder (CKD–MBD), is known to result in resistance to erythropoietin; shortened
survival of RBC via the accumulation of high levels of parathyroid hormone (PTH), a uremic
substance; and decreased hematopoiesis due to myelofibrosis, which partially explains the
pathways linking CKD and anemia[5,6].
It has been reported that parathyroidectomy ameliorates anemia and reduces the require-
ment for postoperative erythropoiesis-stimulating agents. In recent years, vitamin D receptor
activators (VDRA) have been shown to improve anemia in chronic hemodialysis patients
through pleiotropic effects on the immune system, inflammation, and nutritional status, in
addition to the SHPT-related pathways[7–9]. Similar studies have been conducted for the
newly marketed cinacalcet, a calcimimetic drug used to treat SHPT, which is considered to be a
form of pharmacological parathyroidectomy[10,11].
However, the relationship between cinacalcet use and improvement in anemia has not been
clarified in a larger scale longitudinal study. We hypothesized that cinacalcet initiators (patients
who initiate cinacalcet) would experience better anemia control (hemoglobin 10.0 g/dL)
comapred with that experiencedby cinacalcet non-initiators (those who do not initiate cinacal-
cet), after adjusting for both baseline and time-varying confounders. Thus, we conducted a lon-
gitudinal analysis of a large cohort of hemodialysis patients with SHPT in daily clinical practice
to investigate the effect of cinacalcet on improvement of anemia.
Materials and Methods
Data Source
The Mineral and Bone Disorder Outcomes Study for Japanese Chronic Kidney Disease Stage
5D Patients (MBD-5D) was a 3-year, multicenter, prospective case-cohort, and cohort study of
hemodialysis patients with SHPT. The eligibility criteria were as follows: (i) under hemodialysis
at a participating facility as of January 1, 2008 and (ii) intact PTH (iPTH) concentrations 180
pg/mL or receipt of intravenous VDRA (calcitriol or maxacalcitol) or oral active VDRA treat-
ment (falecalcitriol, the only oral VDRA approved in Japan for SHPT treatment at the time of
Cinacalcet Use and Anemia in Hemodialysis Patients
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study conception). Details of the study design have been describedpreviously[12]. Most data
were collected at 3- or 6-month intervals. As hemoglobin was measured every 6 months, we uti-
lized the 6-month interval data in this analysis. This study was approved by the Central Ethics
Committee at the Kobe University School of Medicine. The study was conducted in accordance
with the principles of the Declaration of Helsinki, and the MBD-5D study was registered at
ClinicalTrials.gov (NCT00995163).
Study Population
Only the patients in the predefined subcohort were included in this study. Patients with cancer
or cancer-related comorbidity at the time of enrollment were excluded from the analysis; and if
a patient was diagnosedwith cancer during the observation period, data obtained post-diagno-
sis were not included in the analysis.
Outcomes
The primary outcome of interest was achievement of the target hemoglobin level (10.0 g/dL).
Hemoglobin levels were assessed as the secondary outcome. Both outcomes were repeatedly
measured in each individual every 6 months, up to a maximum of six measurements.
Exposure
Cinacalcet use was the exposure of interest. To emulate the intention-to-treat effect[13] in the
randomized controlled trials, we defined a time-varying “ever exposed” status variable. That is,
patients contributed “unexposed” observations until they initiated cinacalcet; and, once initi-
ated, these patients always contributed “exposed” observations regardless of their current cina-
calcet use status. This time-varying “ever exposed” status was then converted to a “time since
initiation” variable to account for the dose response over time. As the study enrollment period
was prior to the market approval of cinacalcet in Japan, all patients were cinacalcet-naïve at
baseline, allowing for a clear definition of cinacalcet initiation (new user design).
Covariates
Clinically relevant variables that could influence subsequent cinacalcet use and hemoglobin
levels were considered to be confounders that required adjustment. These included demo-
graphics such as age and gender, baseline comorbidities such as the cause of CKD, smoking sta-
tus, diabetes mellitus, heart disease, cerebrovascular disease, and duration of maintenance
hemodialysis history. Any history of hyperparathyroidism treatment (parathyroidectomy, and
ethanol or vitamin D injection therapy) was also assessed at baseline. Baseline-only laboratory
tests included creatinine and total protein. Information on these variables was provided by
each patient’s treating physician.
Comedications and laboratory test values were time-varying.Medications included intrave-
nous or oral activated vitamin D, phosphate binders (either calcium-containing or otherwise),
erythropoiesis-stimulatingagents, and iron supplements. Time-varying laboratory test values
included Kt/V, intact PTH (calculated from the whole PTH level using the equation
iPTH = whole PTH × 1.7 as direct assays differed between study sites)[14,15], albumin-
adjusted serum calcium (calcium–albumin–4.0)[16], serum phosphate, alkaline phosphatase,
albumin, ferritin, iron, and hemoglobin.
To ensure the time-varying covariates, exposure, and outcome were correctly ordered, and
also to avoid reverse causality (where the outcome precedes the covariates), the covariate values
were obtained 6 months prior to the exposure, which in turn was ascertained 6 months prior to
Cinacalcet Use and Anemia in Hemodialysis Patients
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the outcome. In the sensitivity analysis, the lagged exposure status 12 months prior to the out-
come was used to examine the potentially delayed effect of cinacalcet on hemoglobin.
Statistical analysis
Continuous variables were expressed as means and standard deviations or as medians with
25th and 75th percentiles, as appropriate. Categorical variables were summarized as count and
proportion. As the exposure varied over time, we present the baseline characteristics at the
time of study enrollment separately for patients who initiated cinacalcet at some point during
the follow-up and for those who did not start at any time during the follow-up. Group imbal-
ance was examined with the standardizedmean difference[17]; in general, a standardized
mean difference greater than 0.1 was considered as indicating group imbalance. For clinically
relevant variables required for the adjusted regression models, missing values were imputed
with multiple imputation using the mice package in R[18]. Cinacalcet initiation over time was
describedusing Kaplan–Meier estimation techniques. An unadjusted description of mean
hemoglobin level was calculated at each time point for patients who started cinacalcet (“calci-
net users,” in the intention-to-treat sense) and those who remained off cinacalcet (“non-
users”).
In the regression analysis, the generalized estimating equation (GEE) model was used to
account for the within-patient correlation of longitudinal, repeatedly measured outcomes. For
the primary outcome of achievement of the target hemoglobin level (10 g/dL), the GEE longi-
tudinal logisticmodel was used. For the secondary outcome of continuous hemoglobin level,
the GEE longitudinal linear model was used.
Assessment of the effect of time-varying exposure was complicated by the presence of time-
varying confounders, clinical characteristics influenced by previous treatment that affect the
subsequent treatment choices and outcomes of interest[19]. These time-varying characteristics
may therefore be potential confounders and mediators at the same time. To account for these
variables, we employed two strategies: use of the conventional GEE model incorporating time-
varying covariates, and use of a marginal structuralmodel[19].Marginal structuralmodels
with the inverse probability of treatment weighting (IPTW) estimator[19] are increasingly
used to disentangle complex time-varying confounding because they can provide better con-
founding control in such a situation. Due to the longitudinal nature of the outcome data, we
constructed a marginal structuralmodel for the repeatedly measured outcomes[20].
An exploratory analysis among the cinacalcet users assessed changes in iPTH, calcium, and
phosphate and hemoglobin over time. Also an ad hoc subgroup analysis based on the median
iPTH value (265.20 pg/ml) was conducted to examine the influence of the baseline iPTH value
at the study enrollment. All analyses were conducted with R version 3.3 (www.r-project.org)
and its additional packages tableone, mice, geepack, and survey. Hypothesis tests were consid-
ered statistically significant when p< 0.05.
Results
At the baseline, the registery included 3,201 chronic hemodialysis patients with secondary
hyperparathyroidism. Among these, 1,337 patients initiated cinacalcet at some point during the
follow-up (44.6% by the end of follow-up; Fig 1, left panel), constituting the initiators. The
baseline characteristics of the future initiators (none of whomwere on cinacalcet at enrollment)
and the cinacalcet non-users are presented in Table 1. Compared with the non-users, the pro-
spective calcinet users showed the following characteristics at their visit 6 months prior to cina-
calcet initiation: younger age (mean 58.9 years vs 63.9 years), a greater likelihoodof chronic
glomerulonephritis being the reason for hemodialysis (53.3% chronic glomerulonephritis and
Cinacalcet Use and Anemia in Hemodialysis Patients
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15.7% diabetic nephropathy vs 39.1% chronic glomerulonephritis and 30.1% diabetic nephrop-
athy), longer duration of hemodialysis (median 10.9 years vs 5.8 years), more frequent surgical
therapy for secondary hyperparathyroidism (10.8% vs 4.9%), more frequent vitamin D agent
use (86.9% vs 73.8%), more frequent phosphate binder use (91.8% vs 81.6%), slightly more fre-
quent erythropoietic agent use (71.4% vs 69.3%), slightly more frequent iron supplement use
(19.7% vs 14.1%), higher adjusted calcium (mean 10.2 mg/dL vs 9.4 mg/dL), higher inorganic
phosphate (mean 5.8 mg/dL vs 5.4 mg/dL), and slightly higher hemoglobin (10.65 g/dL vs
10.44 g/dL).
The mean hemoglobin levels at each time point for those who had started cinacalcet by that
time and for those who had not are plotted in Fig 1 (right panel). The hemoglobin levels were
slightly higher at each time point for those patients who had started cinacalcet (Users) than for
those who had remained off cinacalcet (Non-users), with the difference varying from 0.1 to 0.2
g/dL. As noted earlier, there were no cinacalcet users at the time of study enrollment. Changes
in several variables before and after cinacalcet initiation are shown in Fig 2. As expected, iPTH
increased steeply before cinacalcet initiation and decreased dramatically afterwards. Serumcal-
cium and phosphate showed a modest decline after initiation. Activated vitamin D doses varied
greatly between individuals; the mean value decreased after cinacalcet initiation. Erythropoie-
sis-stimulating agent use and iron supplement use were stable after initiation of cinacalcet
(around 70% for erythropoiesis-stimulating agent and around 20% for iron supplement).
In the unadjusted GEEmodel (Table 2), the use of cinacalcet for 6 months was associated
with a 1.1-fold increase in the odds of achieving the target hemoglobin level of10 g/dL (odds
ratio 1.13, 95% confidence interval [1.09, 1.17], p< 0.001). The mean change in hemoglobin
level for each additional 6-month use of cinacalcet was +0.064 g/dL [0.047, 0.081], p< 0.001
(Table 3).
The adjusted models were controlled for age, sex, time since enrollment, primary cause of
chronic kidney disease, smoking status, diabetes, ischemic heart disease, congestive heart
Fig 1. Cinacalcet initiation during the follow-up period, and mean hemoglobin level by time-varying cinacalcet status (user or non-user).
doi:10.1371/journal.pone.0164865.g001
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failure, chronic hemodialysis duration, history of surgical therapy for hyperparathyroidism,
baseline creatinine, baseline total protein, comedications (activated vitamin D, phosphate bind-
ers, erythropoietin-stimulatingagents, iron supplements), and laboratorymeasures (Kt/V,
intact parathyroid hormone, albumin-adjusted serum calcium, phosphate, alkaline phospha-
tase, albumin, ferritin, serum iron, and hemoglobin level at the previous visit). The adjusted
Table 1. Characteristics of the cinacalcet non-users at registry enrollment and of the cinacalcet initiators at the visit immediately prior to cinacal-
cet initiation.
Non-users (enrollment) Users (pre-initiation) SMD
N 1864 1337
Age, years (mean (SD)) 63.86 (12.81) 58.88 (11.78) 0.405
Male (%) 1168 (62.7) 800 (59.8) 0.058
Primary disease (%) 0.400
Chronic glomerulonephritis 728 (39.1) 712 (53.3)
Diabetic nephropathy 561 (30.1) 210 (15.7)
Chronic pyelonephritis 31 (1.7) 25 (1.9)
Polycystic kidney 67 (3.6) 72 (5.4)
Hypertensive nephrosclerosis 130 (7.0) 58 (4.3)
Others 347 (18.6) 260 (19.4)
Smoking (%) 202 (10.8) 149 (11.1) 0.010
Diabetes (%) 715 (38.4) 282 (21.1) 0.385
Coronary heart disease (%) 499 (26.8) 298 (22.3) 0.104
Congestive heart failure (%) 158 (8.5) 80 (6.0) 0.096
Cerebrovascular disease (%) 113 (6.3) 58 (4.4) 0.082
Chronic hemodialysis duration, years [median (IQR)] 5.82 [2.53, 11.44] 10.94 [6.81, 16.84] 0.532
History of surgical therapy (%) 92 (4.9) 145 (10.8) 0.221
Parathyroidectomy (%) 84 (4.5) 107 (8.0) 0.145
Ethanol injection (%) 7 (0.4) 32 (2.5) 0.177
Vitamin D injection (%) 10 (0.6) 21 (1.7) 0.102
Baseline creatinine, mg/dL [mean (SD)] 10.74 (2.84) 11.97 (2.73) 0.442
Baseline total protein, g/dL [mean (SD)] 6.57 (0.55) 6.54 (0.53) 0.059
IV or oral activated vitamin D use (%) 1376 (73.8) 1162 (86.9) 0.334
Total activated vitamin D dose Aˆ μg/4 weeks 4.00 [0.00, 7.00] 6.45 [3.50, 9.00] 0.412
Phosphate binder use (%) 1521 (81.6) 1227 (91.8) 0.303
Erythropoietin use (%) 1292 (69.3) 955 (71.4) 0.046
Iron supplement use (%) 263 (14.1) 263 (19.7) 0.149
Body mass index [mean (SD)] 21.35 (3.63) 21.35 (3.27) <0.001
Kt/V [median (IQR)] 1.38 [1.20, 1.56] 1.46 [1.30, 1.62] 0.286
Intact parathyroid hormone, pg/mL [median (IQR)] 237.85 [185.50, 328.02] 340.00 [223.00, 506.60] 0.517
Serum calcium, mg/dL [mean (SD)] 9.13 (0.83) 9.98 (0.73) 1.094
Adjusted serum calcium, mg/dL [mean (SD)] 9.40 (0.95) 10.22 (0.85) 0.908
Serum phosphate, mg/dL [mean (SD)] 5.37 (1.35) 5.80 (1.32) 0.321
Alkaline phosphatase, IU/L [median (IQR)] 248.00 [190.00, 336.50] 256.00 [198.00, 346.00] 0.074
Albumin, g/dL [mean (SD)] 3.73 (0.37) 3.76 (0.35) 0.088
Serum ferritin, ng/mL [mean (SD)] 198.63 (365.08) 148.81 (209.23) 0.167
Serum iron, μg/dL [median (IQR)] 58.00 [44.00, 75.00] 59.00 [45.00, 76.00] 0.002
Hemoglobin, g/dL [mean (SD)] 10.44 (1.19) 10.65 (1.09) 0.182
Hemoglobin < 10 g/dL (%) 600 (32.2) 329 (24.6) 0.169
Abbreviations: SD: standard deviation; IQR: interquartile range; SMD: standardized mean difference
doi:10.1371/journal.pone.0164865.t001
Cinacalcet Use and Anemia in Hemodialysis Patients
PLOS ONE | DOI:10.1371/journal.pone.0164865 October 20, 2016 6 / 13
Fig 2. Trajectories of laboratory findings and medication use for the cinacalcet users before and after cinacalcet initiation.
doi:10.1371/journal.pone.0164865.g002
Table 2. Unadjusted and adjusted effects of each 6 additional months of cinacalcet therapy on the
odds of achieving the treatment target (intention-to-treat effect).
Hemoglobin 10 g/dl as a binary outcome OR [95% CI] p
Generalized estimating equation
Unadjusted 1.13 [1.09, 1.17] <0.001
Fully adjusted 1.08 [1.04, 1.13] <0.001
Inverse probability of treatment weight
Fully adjusted 1.11 [1.04, 1.20] 0.013
Abbreviations: OR: odds ratio; CI: confidence interval.
doi:10.1371/journal.pone.0164865.t002
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regression results for the binary outcome of achievement of target hemoglobin level are pre-
sented in Table 2. The conventional adjusted GEEmodel showed an adjusted odds ratio for
each additional 6-month use of cinacalcet of 1.08 (1.04, 1.13), p< 0.001. The IPTW-based
marginal structuralmodel (Table 2) adjusting for the same set of variables gave a similar result
for the odds of achieving the target hemoglobin level [adjusted odds ratio 1.11 (1.04, 1.20),
p = 0.013].
The adjusted regression results for the outcome of continuous mean hemoglobin levels are
presented in Table 3. The conventional adjusted GEEmodel showed an adjusted effect per
each additional 6 months of cinacalcet use of +0.042 g/dL (0.019, 0.066), p = 0.001. The IPTW-
basedmarginal structuralmodel gave a slightly higher result [adjusted mean difference +0.067
g/dL (0.020, 0.114), p = 0.020].
In the exploratory analysis among the cinacalcet users, the hemoglobin trajectories were
most clearly differentiated throughout the study period between those whose phosphate level
had increased and those whose level had declined. The trajectories were not as clearly separated
by similar differences in iPTH or calcium levels (S1 Fig). In the subgroup analysis, those who
had higher-than-median baseline iPTH had numerically higher improvement in anemia than
those who had lower-than-median baseline iPTH (adjusted odds ratio 1.09 (1.04, 1.14) vs 1.07
(1.00, 1.15) in GEE; adjusted odds ratio 1.14 (1.05, 1.25) vs 1.07 (0.99, 1.17) in IPTW), however,
the group difference did not reach statistical significance (p = 0.657 for GEE; p = 0.304 for
IPTW).
Discussion
In order to clarify the effect of cinacalcet use on the anemia control status, we conducted an
analysis of the MBD-5D prospective cohort of chronic hemodialysis patients. We found that
each additional 6 months on cinacalcet was associated with an approximately 1.1-fold increase
in the odds of maintaining the anemia control target of hemoglobin 10 g/dL.When mea-
sured on the continuous mean hemoglobin-level scale, we also found that each additional 6
months on cinacalcet was associated with a hemoglobin increment of 0.042–0.067 g/dL. These
findings suggest the potential benefit of cinacalcet use for the control of anemia in chronic
hemodialysis patients with SHPT.
SHPT is known to be one of the pathological conditions that cause anemia[21,22], and
SHPT and anemia coexist in most hemodialysis patients. Indeed, as many as 70% of the present
study subjects had anemia and were receiving an erythropoietin-simulatingagent. However, in
routine clinical settings SHPT and anemia are often managed separately and from different
viewpoints.When physicians manage anemia only by controlling the hemoglobin level with
erythropoietin-simulatingagents, few would notice whether the use of cinacalcet improved the
Table 3. Unadjusted and adjusted effects of each 6 additional months of cinacalcet therapy on hemo-
globin levels (intention-to-treat effect).
Hemoglobin value as a continuous outcome Change (g/dL) [95% CI] p
Generalized estimating equation
Unadjusted 0.064 [0.047, 0.081] <0.001
Fully adjusted 0.042 [0.019, 0.066] 0.001
Inverse probability of treatment weight
Fully adjusted 0.067 [0.020, 0.114] 0.02
Abbreviations: CI: confidence interval.
doi:10.1371/journal.pone.0164865.t003
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anemia. The association between cinacalcet use and improvement of anemia in the present
study suggests that it could be possible to manage SHPT and anemia simultaneously in an inte-
grated manner.
Our findings are consistent with the hypothesis, based on the findings of basic science
papers[5,23], that blockage of high parathyroid hormone levels may improve anemia in
patients with secondary hyperparathyroidism. Although non-significant due to reduced sam-
ple sizes, the exploratory subgroup analysis by the baseline iPTH demonstrated numerically
higher effects in those who had higher-than-median baseline iPTH levels. SHPT is known to
cause anemia via several possible pathways. Erythrocyte lifespans decrease in response to high
PTH levels[24]; and high PTH levels inhibit hematopoietic stem cell activity, particularly that
of erythroid burst-forming units, as well as inducingmyelofibrosis and contributing to erythro-
poietin resistance[24,25].
Curative parathyroidectomy has been reported to improve myelofibrosis in patients with
primary hyperparathyroidism, thereby improving anemia[26,27]. Another retrospective report
has described the potential benefits of parathyroidectomy in secondary hyperparathyroidism
[28]. The authors reported that, after parathyroidectomy, the use of erythropoietin-stimulating
agents was rendered unnecessary. These findings suggest that parathyroidectomy induces a
reduction in PTH levels and an improved resistance to vitamin D, thereby inducing improve-
ments in anemia and erythropoietin resistance. This deduction is in accordance with the find-
ings of the present study regarding improvement of anemia with cinacalcet, which is
considered to be a form of “medical parathyroidectomy.”
Cinacalcet is also likely to participate in improving anemia via pathways not driven by PTH
levels. Calcium-sensing receptors play a role in the homing of hematopoietic stem cells to bone
marrow niches as well as in engraftment promotion[29]. The allosteric action of cinacalcet is
likely to act against the calcium-sensing receptors on hematopoietic stem cells, thus contribut-
ing to anemia improvement. Recently, Koizumi et al.[30] reported that administration of cina-
calcet reduced the serum level of fibroblast growth factor 23 in patients with SHPT. Similar
data were also obtained from the EVOLVE study(31). Also, Coe et al.[31] found that loss of
fibroblast growth factor 23 increased erythrocyteproduction in mice. Therefore, in addition to
reducing PTH, reduction of fibroblast growth factor 23 may be one pathway through which
cinacalcet improves anemia.
Our study is not without limitations. As we utilized a cohort of SHPT patients (from the
MBD-5D study), the generalizability of our findings beyond this type of patient (i.e., chronic
hemodialysis patients in general) is unknown. As with any observational studies, problems
with unmeasured (or unmeasurable) confounders cannot be ruled out. The present study did
not record the dosage of comedications that could influence hemoglobin levels (erythropoiesis-
simulating agents and iron supplements), the patients’ activities of daily living, their nutritional
intake status, or inflammatorymarkers. However, these factors are less likely to affect the deci-
sion to initiate cinacalcet (the exposure). Outcome predictors that are not strongly associated
with determining exposure have only limited potential to be confounders[32]. Usage of eryth-
ropoiesis-stimulating agents and iron supplements did not change after cinacalcet initiation.
Thus, we could speculate that their dosage probably did not change dramatically. The mean
ferritin level decreased after cinacalcet initiation, thus, adjustment in anemia treatment may
have benefited these patients further.
Our study had several important strengths. The MBD-5D cohort is a large-scale prospective
cohort of chronic hemodialysis patients, which has collected a rich set of data at regular inter-
vals, allowing assessment of time-varying exposure and the control of time-dependent con-
founding. The cohort’s focus on SHPT patients can be considered as its strength. It allowed us
to analyze a cohort of patients with relatively similar backgrounds. The enrollment period of
Cinacalcet Use and Anemia in Hemodialysis Patients
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the cohort was prior to the market approval of cinacalcet in Japan; thus, no patients were on
cinacalcet at baseline. The new user design is generally recommended in medication studies
[33], as it allows clearer distinction of what prompted medication use, and what resulted from
this. We employed two types of statistical analysis to adjust for time-dependent confounding,
namely the conventional longitudinal GEE model and the IPTW-based marginal structural
model. In this instance, we found relatively similar results from both analyses. The subtle dif-
ferences are likely to be due to the handling of covariates after cinacalcet initiation.
In conclusion, we found that each additional 6 months on cinacalcet was associated with a
1.1-fold increase in the odds of achieving the hemoglobin control target of10 g/dL in chronic
hemodialysis patients with secondary hyperparathyroidism. However, the increment of the
increase in hemoglobin was relatively small, and further investigations are warranted to define
the roles of cinacalcet not only in CKD-MBDmanagement but also in anemia control.
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